Yield10 Bioscience Statistics
Total Valuation
Yield10 Bioscience has a market cap or net worth of 499,342. The enterprise value is 2.53 million.
| Market Cap | 499,342 |
| Enterprise Value | 2.53M |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Yield10 Bioscience has 665,789 shares outstanding. The number of shares has increased by 137.43% in one year.
| Shares Outstanding | 665,789 |
| Shares Change (YoY) | +137.43% |
| Shares Change (QoQ) | +23.90% |
| Owned by Insiders (%) | 18.94% |
| Owned by Institutions (%) | 0.21% |
| Float | 539,657 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.20 |
| EV / Sales | 3.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.43 |
Financial Position
The company has a current ratio of 0.16
| Current Ratio | 0.16 |
| Quick Ratio | 0.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.47 |
| Interest Coverage | -331.39 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -178.11% |
| Return on Capital (ROIC) | -2,867.26% |
| Revenue Per Employee | 25,862 |
| Profits Per Employee | -438,000 |
| Employee Count | 29 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.53% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -90.53% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 3.55 |
| Relative Strength Index (RSI) | 42.52 |
| Average Volume (20 Days) | 5,638 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Yield10 Bioscience had revenue of 750,000 and -12.70 million in losses. Loss per share was -24.93.
| Revenue | 750,000 |
| Gross Profit | -6.46M |
| Operating Income | -12.59M |
| Pretax Income | -12.70M |
| Net Income | -12.70M |
| EBITDA | -12.32M |
| EBIT | -12.59M |
| Loss Per Share | -24.93 |
Balance Sheet
The company has 733,000 in cash and 2.76 million in debt, giving a net cash position of -2.03 million or -3.04 per share.
| Cash & Cash Equivalents | 733,000 |
| Total Debt | 2.76M |
| Net Cash | -2.03M |
| Net Cash Per Share | -3.04 |
| Equity (Book Value) | -6.24M |
| Book Value Per Share | -9.71 |
| Working Capital | -6.47M |
Cash Flow
In the last 12 months, operating cash flow was -5.80 million and capital expenditures -19,000, giving a free cash flow of -5.82 million.
| Operating Cash Flow | -5.80M |
| Capital Expenditures | -19,000 |
| Free Cash Flow | -5.82M |
| FCF Per Share | -8.74 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,679.07% |
| Pretax Margin | -1,693.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -775.73% |
Dividends & Yields
Yield10 Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -137.43% |
| Shareholder Yield | -137.43% |
| Earnings Yield | -3,323.80% |
| FCF Yield | -1,165.13% |
Stock Splits
The last stock split was on May 3, 2024. It was a reverse split with a ratio of 0.0416667.
| Last Split Date | May 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0416667 |
Scores
Yield10 Bioscience has an Altman Z-Score of -214.14. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -214.14 |
| Piotroski F-Score | n/a |